The use of botulinum toxin a in idiopathic overactive bladder syndrome.
Overactive bladder syndrome continues to be a significant burden for the general population. Current first-line medical therapy often includes antimuscarinic medications designed for overactive bladder. Poor efficacy and significant side effects of these antimuscarinic medications have left patients and physicians looking for alternative treatments. There is increasing evidence that intradetrusor injection of botulinum toxin A can effectively treat these patients. We present a current and extensive review of the literature covering the use of botulinum toxin A in patients with overactive bladder with or without idiopathic detrusor overactivity.
Gomez
Christopher S
CS
Department of Urology, University of Miami Miller School of Medicine, 1400 Northwest 10th Avenue, Suite 508, Miami, FL 33136, USA.
Kanagarajah
Prashanth
P
Gousse
Angelo
A
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D000075202:Contraindications; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000009:adverse effects; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D014563:Urodynamics
D018727:Muscarinic Antagonists; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A